These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 23816717

  • 1. Association between pruritus and serum concentrations of parathormone, calcium and phosphorus in hemodialysis patients.
    Tajbakhsh R, Joshaghani HR, Bayzayi F, Haddad M, Qorbani M.
    Saudi J Kidney Dis Transpl; 2013 Jul; 24(4):702-6. PubMed ID: 23816717
    [Abstract] [Full Text] [Related]

  • 2. Frequency of maintenance hemodialysis patients meeting K/DOQI criteria for serum calcium, phosphorus, calcium phosphorus product and PTH levels; a single institutional experience from Pakistan: a cross sectional study.
    Janjua TK, Mukhtar KN, Naveed AK, Ahmed EB, Rehan M.
    Pan Afr Med J; 2019 Jul; 33():183. PubMed ID: 31565143
    [Abstract] [Full Text] [Related]

  • 3. Relationship between serum intact parathyroid hormone and pruritus in hemodialysis patients.
    Makhlough A, Emadi N, Sedighi O, Khademloo M, Bicmohamadi AR.
    Iran J Kidney Dis; 2013 Jan; 7(1):42-6. PubMed ID: 23314141
    [Abstract] [Full Text] [Related]

  • 4. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H, Baradaran A, Naderi AS.
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK.
    Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
    [Abstract] [Full Text] [Related]

  • 7. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK.
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure.
    Zanella MT, Silva MC, Peres RB, Ferreira SR, Draibe SA, Vieira JG.
    Braz J Med Biol Res; 1990 Sep; 23(3-4):235-43. PubMed ID: 2094538
    [Abstract] [Full Text] [Related]

  • 9. Associations of parathyroid hormone levels and mineral parameters with heart rate variability in patients with end-stage renal disease.
    Zhang L, Yang S, Chen J, Ma J, Ren Y.
    Int Urol Nephrol; 2017 Jun; 49(6):1079-1085. PubMed ID: 28243964
    [Abstract] [Full Text] [Related]

  • 10. Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients.
    Lorenzo V, Martín M, Rufino M, Jiménez A, Malo AM, Sanchez E, Hernández D, Rodríguez M, Torres A.
    Am J Kidney Dis; 2001 Jun; 37(6):1260-6. PubMed ID: 11382697
    [Abstract] [Full Text] [Related]

  • 11. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H, Baradaran A.
    J Ayub Med Coll Abbottabad; 2004 Jun; 16(2):3-8. PubMed ID: 15455608
    [Abstract] [Full Text] [Related]

  • 12. Mucocutaneous manifestations and nail changes in patients with end-stage renal disease on hemodialysis.
    Tajbakhsh R, Dehghan M, Azarhoosh R, Haghighi AN, Sadani S, Zadeh SS, Kabootari M, Qorbani M.
    Saudi J Kidney Dis Transpl; 2013 Jan; 24(1):36-40. PubMed ID: 23354189
    [Abstract] [Full Text] [Related]

  • 13. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J, Piecha G, Kokot F, Wiecek A.
    J Nephrol; 2003 Jan; 16(5):710-5. PubMed ID: 14733418
    [Abstract] [Full Text] [Related]

  • 14. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Jan; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 15. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.
    Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK.
    Kidney Int; 2005 Mar; 67(3):1179-87. PubMed ID: 15698460
    [Abstract] [Full Text] [Related]

  • 16. Phosphorus control in peritoneal dialysis patients.
    Yavuz A, Ersoy FF, Passadakis PS, Tam P, Evaggelos DM, Katopodis KP, Ozener C, Akçiçek F, Camsari T, Ateş K, Ataman R, Vlachojannis GJ, Dombros NA, Utaş C, Akpolat T, Bozfakioğlu S, Wu G, Karayaylali I, Arinsoy T, Stathakis CP, Yavuz M, Tsakiris DJ, Dimitriades AC, Yilmaz ME, Gültekin M, Süleymanlar G, Oreopoulos DG.
    Kidney Int Suppl; 2008 Apr; (108):S152-8. PubMed ID: 18379539
    [Abstract] [Full Text] [Related]

  • 17. Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015).
    Al Salmi I, AlRukhaimi M, AlSahow A, Shaheen FA, Al-Ghamdi SM, AlAli F, AlGhareeb S, Al Maimani Y, AlGhonaim M, Bieber B, Tentori F, Pisoni RL, GCC-DOPPS 5 Study GroupStudy Group in Acknowledgment..
    Saudi J Kidney Dis Transpl; 2016 Nov; 27(6 Suppl 1):62-80. PubMed ID: 27991480
    [Abstract] [Full Text] [Related]

  • 18. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L, Carboni C, Stipo L, Malaguti V, Ferrari F, Graziani R, Arletti S, Graziosi C.
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [Abstract] [Full Text] [Related]

  • 19. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F, Corradi B, Imbasciati E.
    Adv Perit Dial; 1996 Dec; 12():239-44. PubMed ID: 8865912
    [Abstract] [Full Text] [Related]

  • 20. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF, el-Shahawy M, Andrews G, Ibrahim M, Ramdeen G, Hanna D, Gorospe W, Morkos A, Abbassian M, Moles K.
    Adv Perit Dial; 2001 Dec; 17():29-36. PubMed ID: 11510292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.